Comparison of azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children in Africa: a randomized, open-label study

Richa Chandra, Patrick Ansah, Issaka Sagara, Ali Sie, Alfred B Tiono, Abdoulaye A Djimde, Qinying Zhao, Jeffery Robbins, Louis K Penali, Bernhards Ogutu, Richa Chandra, Patrick Ansah, Issaka Sagara, Ali Sie, Alfred B Tiono, Abdoulaye A Djimde, Qinying Zhao, Jeffery Robbins, Louis K Penali, Bernhards Ogutu

Abstract

Background: This randomized, open-label study was conducted to establish the non-inferiority of a combination of azithromycin (AZ) and chloroquine (CQ) to artemether-lumefantrine (AL) for treatment of uncomplicated malaria in children from six sites in sub-Saharan Africa.

Methods: Children with uncomplicated Plasmodium falciparum malaria between six and 59 months of age were randomized 1:1 to either AZCQ (30 mg/kg AZ + 10 mg/kg CQ base) or AL per prescribing information for three days (Days 0, 1, 2). Each site could enrol in the study population once the treatment of uncomplicated malaria in five children five to 12 years of age was deemed to be effective and well tolerated. The primary efficacy evaluation was the proportion of subjects in both the modified intent-to-treat (MITT) and per-protocol (PP) populations with an adequate clinical and parasitological response (PCR corrected) at Day 28. Non-inferiority was concluded if the lower bound of the 95% confidence interval comparing the two groups was 10 percentage points or greater.

Results: A total of 255 children were enrolled in the efficacy analysis (AZCQ, n = 124; AL, n = 131). The PCR corrected clearance rates were 89% (AZCQ) versus 98% (AL) for MITT, a difference of -9.10 (95% confidence interval; -16.02, -2.18) and 93% (AZCQ) versus 99% (AL) for PP, a difference of -6.08 (-12.10, -0.05). Early and late treatment failures were more common in subjects receiving AZCQ. Adverse events were more common in subjects treated with AZCQ. Drug concentrations obtained at specified time points following AZCQ administration had a large coefficient of variation partially due to sparse sampling with sample collection time window.

Conclusions: In this study, non-inferiority of AZCQ to AL was not demonstrated.

Trial registration: ClinicalTrials.gov NCT00677833 .

Figures

Figure 1
Figure 1
Subject disposition (Cohort 2). AE = adverse event, AL = artemether-lumefantrine, AZCQ = azithromycin-chloroquine fixed-dose combination, MITT = modified intent-to-treat, PP = per protocol. *Includes 1 subject who discontinued treatment due to an AE.

References

    1. WHO . World Malaria Report 2013. Geneva: World Health Organization; 2013.
    1. WHO . Malaria. Overview of treatment. Geneva: World Health Organization; 2013.
    1. Biswas S. In-vitro antimalarial activity of azithromycin against chloroquine sensitive and chloroquine resistant Plasmodium falciparum. J Postgrad Med. 2001;47:240–3.
    1. Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, Dev V, et al. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis. 2005;191:1582–8. doi: 10.1086/429343.
    1. Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 2002;46:2518–24. doi: 10.1128/AAC.46.8.2518-2524.2002.
    1. Lewis D, Mulenga M, Mugyenyi P, Sagara I, Wasunna M, Oduro A, et al. A phase 2/3, randomized, double blind, comparative trial of azithromycin plus chloroquine vs. mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in Africa. Trop Med Int Health. 2007;12:82–3. doi: 10.1111/j.1365-3156.2007.01945.x.
    1. Sagara I, Oduro A, Mulenga M, Dieng Y, Ogutu B, Tiono AB, et al. Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. 2014;13:458.
    1. Chandra R, Lewis D, Moran D, Dubhashi N, Sarkar S, Wang CS, et al. A phase 2, open label, non-comparative trial of azithromycin 2 g plus chloroquine 600 mg base daily for three days for the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2008;79(Suppl 6):110.
    1. Lewis D, Carrasquilla G, Vreden S, Utz G, Sarkar S, Montilla D, et al. A phase 2/3, randomized, double-blind, comparative trial of azithromycin plus chloroquine vs. atovaquone-proguanil for the treatment of uncomplicated Plasmodium falciparum malaria in South America. Trop Med Int Health. 2007;12(Suppl 1):83–4.
    1. Lewis D, Kshirsagar NA, Bhattacharyya P, Mishra K, Dubhashi N, Gosavi R, et al. A phase 2/3, randomized, comparative trial of azithromycin plus chloroquine vs. sulfadoxine-pyrimethamine plus chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in India. Trop Med Int Health. 2007;12(Suppl 1):83.
    1. Chandra RS, Orazem J, Ubben D, Duparc S, Robbins J, Vandenbroucke P. Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa. Malar J. 2013;12:122. doi: 10.1186/1475-2875-12-122.
    1. Zhao Q, Purohit V, Cai J, LaBadie RR, Chandra RS. Relative bioavailability of a fixed-combination tablet formulation of azithromycin and chloroquine in healthy adult subjects. J Bioequiv Availab. 2013;5:1. doi: 10.4172/jbb.1000127.
    1. Ranford-Cartwright LC, Taylor J, Umasunthar T, Taylor LH, Babiker HA, Lell B, et al. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg. 1997;91:719–24. doi: 10.1016/S0035-9203(97)90539-3.
    1. Sagara I, Dicko A, Djimde A, Guindo O, Kone M, Tolo Y, et al. A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg. 2006;75:630–6.
    1. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, Do Rosario VE, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315–20. doi: 10.1016/0166-6851(93)90077-B.
    1. Su X, Wellems TE. Toward a high-resolution Plasmodium falciparum linkage map: polymorphic markers from hundreds of simple sequence repeats. Genomics. 1996;33:430–44. doi: 10.1006/geno.1996.0218.
    1. WHO . Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva, Switzerland: World Health Organization; 2003.
    1. WHO: Global report on antimalarial drug efficacy and drug resistance: 2000–2010. World Health Organization, Geneva. Available at: . Access November 19, 2013.
    1. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA. 2007;297:2210–9. doi: 10.1001/jama.297.20.2210.
    1. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis. 2007;45:1453–61. doi: 10.1086/522985.
    1. Sagara I, Oduru AR, Mulenga M, Dieng Y, Ogutu B, Tiono AB, et al. Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomized clinical trials in African adults. Malar J. 2014;13:458. doi: 10.1186/1475-2875-13-458.
    1. Thriemer K, Starzengruber P, Khan WA, Haque R, Marma AS, Ley B, et al. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J Infect Dis. 2010;202:392–8. doi: 10.1086/653710.
    1. Sykes A, Hendriksen I, Mtove G, Mandea V, Mrema H, Rutta B, et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis. 2009;49:1195–201. doi: 10.1086/605635.
    1. Laufer MK, Thesing PC, Dzinjalamala FK, Nyirenda OM, Masonga R, Laurens MB, et al. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PLoS One. 2012;7:e42284. doi: 10.1371/journal.pone.0042284.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever